A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study) - NURTURE

CB Celltech0 个研究点目标入组 100 人开始时间: 2015年3月2日最近更新: 2015年3月9日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 100

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Subjects with active Crohn's Disease (CD) confirmed 3 months prior to Screening
•- Subjects with a Pediatric Crohn's Disease Activity Index (PCDAI) score of > 30 at Week 0
•- Subjects between the ages of 6 and 17, inclusive, prior to baseline dosing
•- Subjects must weigh > 20 kg (44 lbs)
•- Subjects must have normal Electrocardiogram (ECG) or no medically relevant abnormalities as assessed by the investigator
•- Subjects must meet Tuberculosis (TB) screening criteria
•- Subjects taking corticosteroids, antibiotics and analgesics must have stable dosing, as defined, for one week
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 100
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range 0
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 0

排除标准

•- Subjects who score > 5 on the perirectal disease item of the PCDAI at Baseline
•- Subjects who have had an active enterocutaneous fistulae within 3 months prior to Baseline
•- Subjects with non-enterocutaneous fistulae, signs or symptoms of bowel obstruction or short bowel syndrome
•- Subjects with a functional colostomy or ileostomy
•- Subjects who have had surgical bowel resection within 6 months prior to Baseline or who may be planning any resection while enrolled in the study
•- Subjects with clinical suspicion of intraabdominal abscesses
•- Subjects with a positive stool result for enteric pathogens and/or parasites
•- Subject has received any investigational biological therapies (within or outside a clinical trial) within 12 weeks prior to Screening or has been dosed in any clinical trial using non biological therapies within 4 weeks prior to Screening
•- Subjects who have lost response to another Tumor Necrosis Factor (TNF) agent
•- Subjects may not use another TNF agent within 12 weeks of Screening Visit
•- Subjects with any prior exposure to natalizumab
•- Subjects who have received mycophenolate or thalidomide within 4 weeks prior to Screening
•- Subjects who have received cyclosporin or tacrolimus within 6 months prior to Screening
•- Subjects who have received parenteral corticosteroids within 2 weeks prior to Screening
•- Subjects who have received corticosteroids or corticotrophins for indications other than CD within 2 weeks of Screening
•- Subject has a current or recent history (within 6 months prior to Screening) of significant and severe renal, hepatic, hematological, gastrointestinal (other than CD), endocrine, pulmonary, cardiac, neurological, or cerebral disease including blood dyscrasia (eg, pancytopenia, aplastic anemia), demyelinating disease (eg, multiple sclerosis, myelitis, optic neuritis), or ischemic heart disease
•- Subjects with a current sign or symptom indicating recent or chronic infections (including herpes zoster)
•- Subject has negative test for Immunoglobulin G (IgG) against Varicella zoster (chicken pox)
•- Subjects who have not completed their primary vaccination series, or are planning to have a live vaccine administered during the study period or up to 3 months after last dose of study drug
•- Subject has a history of TB or a positive chest x-ray suggestive of TB
•- Subjects with known concurrent viral hepatitis or Acquired Immune Deficiency Syndrome (AIDS) or known Human Immunodeficiency Virus (HIV) infection
•- Subjects with concurrent malignancy or history of malignancy, excluding treated squamous cell carcinoma of the skin
•- Subject has concurrent bowel dysplasia or a history of bowel dysplasia in the 5 years prior to Screening
•- Subjects with a history lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoma at any time

研究者

发起方

CB Celltech

相似试验

已完成

2 期

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)ide Analogs in Participants With Chronic Hepatitis B Virus InfectioHepatitis B, Chronic

JPRN-jRCT2061210044akama Takahiro102

进行中（未招募）

1 期

A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection.Chronic Hepatitis B Virus InfectionMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestations

EUCTR2021-002450-81-PLJanssen-Cilag International NV102

进行中（未招募）

1 期

EUCTR2021-002450-81-ESJanssen-Cilag International NV102

进行中（未招募）

1 期

A clinical trial to evaluate if apremilast is safe in children and adolescents with moderate to severe plaque psoriasis as well as assessing how apremilast is processed by the body, and to determine the appropriate dose for themModerate to severe plaque psoriasis in adolescents (ages 12 to 17 years, inclusive) and in children (ages 6 to 11 years, inclusive).MedDRA version: 18.1 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders

EUCTR2015-003314-24-ESCelgene Corporation32

进行中（未招募）

不适用

A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of OralOPC-34712 as Monotherapy in Adult Patients with SchizophreniaMedDRA version: 12.0Level: LLTClassification code 10039626Term: Schizophreniaschizophrenia

EUCTR2009-012568-14-SKOtsuka Pharmaceutical Development & Commercialization300